مصطلحات الفهرس: prednisolone/cb [Drug Combination], adult, aged, article, bone marrow biopsy, cancer combination chemotherapy, cancer immunotherapy, cancer mortality, cancer radiotherapy, cancer recurrence, cancer staging, cohort analysis, comparative effectiveness, controlled study, distant metastasis/co [Complication], female, follicular lymphoma/dt [Drug Therapy], follicular lymphoma/rt [Radiotherapy], follow up, human, human tissue, lymph node metastasis/co [Complication], maintenance therapy, major clinical study, male, monotherapy, multimodality cancer therapy, overall survival, positron emission tomography-computed tomography, priority journal, progression free survival, radiation dose, retrospective study, survival rate, survival time, systemic therapy, treatment failure, treatment outcome, watchful waiting, bendamustine/cb [Drug Combination], bendamustine/dt [Drug Therapy], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], hemoglobin/ec [Endogenous Compound], prednisolone/dt [Drug Therapy], rituximab/cb [Drug Combination], rituximab/dt [Drug Therapy], rituximab/tm [Unexpected Outcome of Drug Treatment], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35979Test
Click here for full text options
LibKey Link

مصطلحات الفهرس: positron emission tomography, cancer prognosis, cancer recurrence, cancer staging, cancer survival, Chlamydia psittaci, computer assisted tomography, drug effect, drug targeting, event free survival, fluorescence in situ hybridization, Helicobacter pylori, Hepatitis C virus, human, mantle cell lymphoma/di [Diagnosis], mantle cell lymphoma/dt [Drug Therapy], marginal zone lymphoma/di [Diagnosis], marginal zone lymphoma/dt [Drug Therapy], multiple cycle treatment, nonhuman, overall survival, priority journal, progression free survival, review, survival time, treatment duration, treatment outcome, treatment planning, tumor biopsy, bendamustine/cb [Drug Combination], bendamustine/dt [Drug Therapy], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], cytarabine/dt [Drug Therapy], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], fludarabine/cb [Drug Combination], fludarabine/dt [Drug Therapy], methotrexate/cb [Drug Combination], methotrexate/dt [Drug Therapy], prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], prednisone/cb [Drug Combination], prednisone/dt [Drug Therapy], rituximab/cb [Drug Combination], rituximab/dt [Drug Therapy], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], Australia, Borrelia burgdorferi, Campylobacter jejuni, cancer combination chemotherapy, cancer immunotherapy, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35992Test
Internal Medicine Journal
Click here for full text options
LibKey Link

مصطلحات الفهرس: cancer survival, clinical outcome, comorbidity, drug efficacy, drug tolerability, follicular lymphoma/di [Diagnosis], follicular lymphoma/dt [Drug Therapy], human, immunoregulation, infection/si [Side Effect], maintenance therapy, medical decision making, nonhodgkin lymphoma/di [Diagnosis], nonhodgkin lymphoma/dt [Drug Therapy], obinutuzumab/cb [Drug Combination], patient monitoring, patient preference, priority journal, progression free survival, review, second cancer/si [Side Effect], survival time, symptom, T cell depletion, treatment duration, treatment response, tumor volume, bendamustine/ae [Adverse Drug Reaction], bendamustine/cb [Drug Combination], bendamustine/dt [Drug Therapy], CD20 antibody/cb [Drug Combination], CD20 antibody/dt [Drug Therapy], obinutuzumab/dt [Drug Therapy], prednisolone/ae [Adverse Drug Reaction], prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/cb [Drug Combination], rituximab/dt [Drug Therapy], vincristine/ae [Adverse Drug Reaction], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], overall survival, cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], doxorubicin/ae [Adverse Drug Reaction], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], lenalidomide/dt [Drug Therapy], advanced cancer/di [Diagnosis], age, asymptomatic disease/di [Diagnosis], Australia, cancer combination chemotherapy, cancer diagnosis, cancer immunotherapy, cancer recurrence, cancer staging, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35707Test
Internal Medicine Journal
LibKey Link

مصطلحات الفهرس: prednisolone/cb [Drug Combination], adult, aged, article, bone marrow biopsy, cancer combination chemotherapy, cancer immunotherapy, cancer mortality, cancer radiotherapy, cancer recurrence, cancer staging, cohort analysis, comparative effectiveness, controlled study, distant metastasis/co [Complication], female, follicular lymphoma/dt [Drug Therapy], follicular lymphoma/rt [Radiotherapy], follow up, human, human tissue, lymph node metastasis/co [Complication], maintenance therapy, major clinical study, male, monotherapy, multimodality cancer therapy, overall survival, positron emission tomography-computed tomography, priority journal, progression free survival, radiation dose, retrospective study, survival rate, survival time, systemic therapy, treatment failure, treatment outcome, watchful waiting, bendamustine/cb [Drug Combination], bendamustine/dt [Drug Therapy], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], hemoglobin/ec [Endogenous Compound], prednisolone/dt [Drug Therapy], rituximab/cb [Drug Combination], rituximab/dt [Drug Therapy], rituximab/tm [Unexpected Outcome of Drug Treatment], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35979Test
LibKey Link

مصطلحات الفهرس: positron emission tomography, cancer prognosis, cancer recurrence, cancer staging, cancer survival, Chlamydia psittaci, computer assisted tomography, drug effect, drug targeting, event free survival, fluorescence in situ hybridization, Helicobacter pylori, Hepatitis C virus, human, mantle cell lymphoma/di [Diagnosis], mantle cell lymphoma/dt [Drug Therapy], marginal zone lymphoma/di [Diagnosis], marginal zone lymphoma/dt [Drug Therapy], multiple cycle treatment, nonhuman, overall survival, priority journal, progression free survival, review, survival time, treatment duration, treatment outcome, treatment planning, tumor biopsy, bendamustine/cb [Drug Combination], bendamustine/dt [Drug Therapy], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], cytarabine/dt [Drug Therapy], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], fludarabine/cb [Drug Combination], fludarabine/dt [Drug Therapy], methotrexate/cb [Drug Combination], methotrexate/dt [Drug Therapy], prednisolone/cb [Drug Combination], prednisolone/dt [Drug Therapy], prednisone/cb [Drug Combination], prednisone/dt [Drug Therapy], rituximab/cb [Drug Combination], rituximab/dt [Drug Therapy], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], Australia, Borrelia burgdorferi, Campylobacter jejuni, cancer combination chemotherapy, cancer immunotherapy, Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35992Test
Internal Medicine Journal
LibKey Link

مصطلحات الفهرس: infection/si [Side Effect], infusion related reaction/si [Side Effect], intention to treat analysis, major clinical study, male, multiple cycle treatment, myelodysplastic syndrome/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], non melanoma skin cancer/si [Side Effect], primary health care, priority journal, progression free survival, cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], doxorubicin/ae [Adverse Drug Reaction], doxorubicin/ct [Clinical Trial], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], obinutuzumab/ae [Adverse Drug Reaction], obinutuzumab/ct [Clinical Trial], obinutuzumab/dt [Drug Therapy], obinutuzumab/iv [Intravenous Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/dt [Drug Therapy], vincristine/ae [Adverse Drug Reaction], vincristine/ct [Clinical Trial], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], randomized controlled trial, second cancer/si [Side Effect], thrombocytopenia/si [Side Effect], treatment outcome, treatment response, tumor lysis syndrome/si [Side Effect], very elderly, bendamustine/ae [Adverse Drug Reaction], bendamustine/ct [Clinical Trial], bendamustine/cb [Drug Combination], bendamustine/dt [Drug Therapy], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], adult, aged, article, bleeding disorder/si [Side Effect], cancer grading, cancer growth, cancer immunotherapy, cancer recurrence, cardiovascular disease/si [Side Effect], controlled study, digestive system perforation/si [Side Effect], female, follicular lymphoma/dt [Drug Therapy], hematologic malignancy/si [Side Effect], human, induction chemotherapy, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38731Test
New England Journal of Medicine
Click here for full text options
LibKey Link

مصطلحات الفهرس: infection/si [Side Effect], infusion related reaction/si [Side Effect], intention to treat analysis, major clinical study, male, multiple cycle treatment, myelodysplastic syndrome/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], non melanoma skin cancer/si [Side Effect], primary health care, priority journal, progression free survival, cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], doxorubicin/ae [Adverse Drug Reaction], doxorubicin/ct [Clinical Trial], doxorubicin/cb [Drug Combination], doxorubicin/dt [Drug Therapy], obinutuzumab/ae [Adverse Drug Reaction], obinutuzumab/ct [Clinical Trial], obinutuzumab/dt [Drug Therapy], obinutuzumab/iv [Intravenous Drug Administration], prednisone/ae [Adverse Drug Reaction], prednisone/ct [Clinical Trial], prednisone/cb [Drug Combination], prednisone/dt [Drug Therapy], rituximab/ae [Adverse Drug Reaction], rituximab/ct [Clinical Trial], rituximab/dt [Drug Therapy], vincristine/ae [Adverse Drug Reaction], vincristine/ct [Clinical Trial], vincristine/cb [Drug Combination], vincristine/dt [Drug Therapy], randomized controlled trial, second cancer/si [Side Effect], thrombocytopenia/si [Side Effect], treatment outcome, treatment response, tumor lysis syndrome/si [Side Effect], very elderly, bendamustine/ae [Adverse Drug Reaction], bendamustine/ct [Clinical Trial], bendamustine/cb [Drug Combination], bendamustine/dt [Drug Therapy], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/ct [Clinical Trial], adult, aged, article, bleeding disorder/si [Side Effect], cancer grading, cancer growth, cancer immunotherapy, cancer recurrence, cardiovascular disease/si [Side Effect], controlled study, digestive system perforation/si [Side Effect], female, follicular lymphoma/dt [Drug Therapy], hematologic malignancy/si [Side Effect], human, induction chemotherapy, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38731Test
New England Journal of Medicine
Click here for full text options
LibKey Link